Zai Lab
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their...
Latest News
15 hours ago · seekingalpha.com
Zai Lab: Tarlatamab's First-Line Win Makes Zoci The DLL3 Partner Of ChoiceZai Lab looks underappreciated as the wholly owned developer of zoci, a potential DLL3 treatment backbone, rather than merely a China distributor. Amgen and Boehringer are funding zoci combination studies; first-line data showed an 81.8% response rate across 33 evaluable patients. I estimate roughly ten quarters of debt-adjusted cash runway at elevated trial spending, while management expects product revenue growth to return in 2027.
3 days ago · businesswire.com
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth ProductsSHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country's 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for gMG and schizophrenia, and three renewals, which maintain access across oncology and infectious disease. Zai Lab Products Newly.
3 days ago · businesswire.com
Zai Lab Announces Participation in Investor Conferences in November 2026SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in November 2026: UBS Global Biopharma Conference Date: November 17, 2026 Event Format: 1-on-1 meetings only Location: London, UK Jefferies Global Healthcare Conference in London Date: November 18 and 19, 2026 Fireside Chat: Wednesday, November 18, 2026 at 10:30AM GMT Event Format: Pre.
3 days ago · benzinga.com
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance DosingZai Lab Limited (NASDAQ:ZLAB) reported preliminary results from the first-in-human portion of its global Phase 1/1b clinical trial evaluating ZL-1503, an investigational bispecific antibody for moderate-to-severe atopic dermatitis.
3 days ago · seekingalpha.com
Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans TranscriptZai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
3 days ago · businesswire.com
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent DosingSHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced positive preliminary, first-in-human results from the single-ascending-dose portion of its global Phase 1/1b trial of ZL-1503, an internally discovered, long-acting IL-13/IL-31 receptor alpha (Rα) bispecific antibody. Findings from the study will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scien.
6 days ago · zacks.com
Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?The consensus price target hints at a 40.2% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
10 days ago · marketbeat.com
Zai Lab Q3 Earnings Call HighlightsZai Lab NASDAQ: ZLAB reported $108.2 million in third-quarter revenue and said it expects to return to year-over-year product revenue growth in 2027, while advancing its lead cancer drug candidate toward potential U.S. regulatory submissions next year.
11 days ago · seekingalpha.com
Zai Lab Limited (ZLAB) Q3 2026 Earnings Call TranscriptZai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesWhile the top- and bottom-line numbers for Zai Lab Limited (ZLAB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ZLAB